Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
P/B ratio for Precipio, Inc. (PRPO)
P/B ratio as of 2023: 0.58
According to Precipio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.58. At the end of 2022 the company had a P/B ratio of 0.77.
P/B ratio history for Precipio, Inc. from 1999 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.58 |
| 2022 | 0.77 |
| 2021 | 1.36 |
| 2020 | 2.41 |
| 2019 | 0.88 |
| 2018 | 0.54 |
| 2017 | 0.43 |
| 2016 | -0.01 |
| 2015 | -0.29 |
| 2014 | 6.86 |
| 2013 | 3.81 |
| 2012 | 1.71 |
| 2011 | 2.23 |
| 2010 | 2.90 |
| 2009 | 2.11 |
| 2008 | 1.86 |
| 2007 | 1.74 |
| 2006 | 1.53 |
| 2005 | 1.00 |
| 2004 | 0.88 |
| 2003 | 0.27 |
| 2002 | 0.19 |
| 2001 | 0.14 |
| 2000 | 0.11 |
| 1999 | -3.10 |